Powered 500 · 2026POWEREDS. 259 of 500
Under Blue's leadership, HistoSonics won FDA authorization for the Edison system — a focused sound-wave device that destroys liver tumors without radiation, needles, or incisions — and is now expanding it across leading U.S. cancer centers as a genuinely new oncology modality.
Mike Blue leads HistoSonics, a medical device company developing histotripsy, a non-invasive sonic beam therapy that destroys liver tumors without radiation, needles, or incisions.
The company's Edison system received FDA authorization for liver tumor treatment and has expanded across leading U.S. cancer centers, with clinical development underway for additional tumor types. Blue was a 2025 EY Entrepreneur of the Year National Health Award finalist.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
